

The interaction of visceral leishmaniasis (kala azar) with HIV/AIDS adds considerable complexity to the treatment of both diseases.
Prevention of VL in people living with HIV in VL-endemic areas should be promoted and diagnosis and treatment of VL in HIV-positive patients should be scaled up.